Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the New England Journal of Medicine has published the Phase 3 HERIZON-GEA-01 trial results, further characterizing the efficacy and safety ...
CIDRAP

Phase 3 trials of novel drug show functional cure in 20% of chronic hepatitis B patients

Two replicate phase 3 randomized controlled trials involving patients with chronic hepatitis B virus (HBV) infection demonstrate a functional cure after the discontinuation of conventional long-term ...

GSK’s hepatitis B drug touts functional curative potential in double Phase III win

Analysts are heralding bepirovirsen as a potentially strong future growth driver for GSK and its infectious disease portfolio.

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 ...
The New England Journal of Medicine

Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.

GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript

Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment May 28, 2026 10:00 AM EDTCompany ParticipantsConstantin Fest ...